Banbakt Use In Pregnancy & Lactation

Pregnancy: Animal studies demonstrated reproductive toxicity of clindamycin, which was used parenterally or orally.
During the first trimester of pregnancy, vaginal suppositories with clindamycin are not recommended because of lack of appropriate studies.
Intravaginal use of clindamycin in the form of a cream during the second trimester of pregnancy, as well as systemic application of clindamycin phosphate during the second and third trimesters did not lead to any pathological effects on the fetus. Therefore, vaginal suppositories with clindamycin can be used during the second and third trimesters of pregnancy only when clearly needed. During pregnancy, it is recommended to administer vaginal suppositories without the use of an applicator.
Lactation: It is not known if clindamycin is excreted in breast milk following the use of vaginally administered clindamycin phosphate. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Therefore, a full assessment of benefit-risk should be made when consideration is given to using vaginal clindamycin phosphate in a nursing mother.
Fertility: Studies in animals revealed no evidence on impaired fertility.